Homestead Advisers Corp Bristol Myers Squibb CO Transaction History

Homestead Advisers Corp

  • $3.96 Billion
  • Q3 2025

A detailed history of Homestead Advisers Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Homestead Advisers Corp holds 424,389 shares of BMY stock, worth $19.8 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
424,389
Previous 964,189 55.98%
Holding current value
$19.8 Million
Previous $44.6 Million 57.12%
% of portfolio
0.48%
Previous 1.12%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025
SELL
$43.31 - $48.98 $23.4 Million - $26.4 Million
-539,800 Reduced 55.98%
424,389 $19.1 Million
Q2 2025

Aug 05, 2025
BUY
$44.12 - $59.6 $163,244 - $220,520
3,700 Added 0.39%
964,189 $44.6 Million
Q4 2024

Feb 12, 2025
BUY
$51.92 - $59.94 $1.86 Million - $2.15 Million
35,800 Added 3.87%
960,489 $54.3 Million
Q3 2024

Nov 01, 2024
SELL
$39.66 - $51.75 $27,761 - $36,225
-700 Reduced 0.08%
924,689 $47.9 Million
Q2 2024

Jul 23, 2024
SELL
$40.25 - $52.99 $639,975 - $842,541
-15,900 Reduced 1.69%
925,389 $38.4 Million
Q1 2024

May 10, 2024
SELL
$47.98 - $54.4 $62,373 - $70,720
-1,300 Reduced 0.14%
941,289 $51 Million
Q4 2023

Feb 13, 2024
BUY
$48.48 - $57.85 $77,568 - $92,560
1,600 Added 0.17%
942,589 $48.4 Million
Q3 2023

Nov 09, 2023
BUY
$57.89 - $64.73 $839,405 - $938,585
14,500 Added 1.57%
940,989 $54.6 Million
Q2 2023

Jul 25, 2023
BUY
$63.71 - $70.74 $286,695 - $318,330
4,500 Added 0.49%
926,489 $59.2 Million
Q1 2023

Apr 27, 2023
BUY
$65.71 - $74.53 $6.64 Million - $7.53 Million
101,000 Added 12.3%
921,989 $63.9 Million
Q4 2022

Feb 03, 2023
BUY
$68.48 - $81.09 $13,696 - $16,218
200 Added 0.02%
820,989 $59.1 Million
Q3 2022

Nov 07, 2022
SELL
$0.13 - $76.84 $3,432 - $2.03 Million
-26,400 Reduced 3.12%
820,789 $58.4 Million
Q1 2022

May 12, 2022
SELL
$61.48 - $73.72 $7.8 Million - $9.36 Million
-126,900 Reduced 13.03%
847,189 $61.9 Million
Q4 2021

Feb 07, 2022
SELL
$53.63 - $62.52 $386,136 - $450,144
-7,200 Reduced 0.73%
974,089 $60.7 Million
Q3 2021

Nov 05, 2021
BUY
$59.17 - $69.31 $230,763 - $270,309
3,900 Added 0.4%
981,289 $58.1 Million
Q2 2021

Aug 02, 2021
SELL
$61.91 - $67.42 $841,976 - $916,912
-13,600 Reduced 1.37%
977,389 $65.3 Million
Q1 2021

May 07, 2021
SELL
$59.34 - $66.74 $3 Million - $3.37 Million
-50,500 Reduced 4.85%
990,989 $62.6 Million
Q4 2020

Feb 10, 2021
SELL
$57.74 - $65.43 $1.46 Million - $1.66 Million
-25,300 Reduced 2.37%
1,041,489 $64.6 Million
Q3 2020

Nov 13, 2020
SELL
$57.43 - $63.64 $6.79 Million - $7.52 Million
-118,200 Reduced 9.97%
1,066,789 $64.3 Million
Q2 2020

Aug 13, 2020
BUY
$54.82 - $64.09 $87,712 - $102,544
1,600 Added 0.14%
1,184,989 $69.7 Million
Q1 2020

May 14, 2020
SELL
$46.4 - $67.43 $1.59 Million - $2.31 Million
-34,288 Reduced 2.82%
1,183,389 $66 Million
Q4 2019

Feb 13, 2020
SELL
$49.21 - $64.19 $572,312 - $746,529
-11,630 Reduced 0.95%
1,217,677 $78.2 Million
Q3 2019

Nov 14, 2019
SELL
$42.77 - $50.71 $5.13 Million - $6.09 Million
-120,023 Reduced 8.9%
1,229,307 $62.3 Million
Q2 2019

Aug 12, 2019
SELL
$44.62 - $49.34 $45.8 Million - $50.6 Million
-1,025,670 Reduced 43.19%
1,349,330 $61.2 Million
Q1 2019

May 14, 2019
SELL
$45.12 - $53.8 $14.7 Million - $17.5 Million
-325,000 Reduced 12.04%
2,375,000 $113 Million
Q3 2017

Nov 13, 2017
BUY
$55.23 - $63.74 $149 Million - $172 Million
2,700,000
2,700,000 $172 Million

Others Institutions Holding BMY

# of Institutions
2,668
Shares Held
1.56B
Call Options Held
24.3M
Put Options Held
25.7M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $99.2B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Homestead Advisers Corp Portfolio

Follow Homestead Advisers Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Homestead Advisers Corp, based on Form 13F filings with the SEC.

News

Stay updated on Homestead Advisers Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email